Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6

U Ganter, R Arcone, C Toniatti, G Morrone, G Ciliberto, U Ganter, R Arcone, C Toniatti, G Morrone, G Ciliberto

Abstract

Human C-reactive protein (CRP) is the major acute phase reactant during acute inflammation. The human CRP promoter is expressed in an inducible and cell-specific manner when linked to the bacterial CAT gene and transfected into human hepatoma cell cultures. In this paper we analyze the effect of several recombinant cytokines or CRP promoter inducibility in human Hep3B cells. When cytokines are tested singly the major inducer of CRP-CAT fusions is interleukin-6 (IL-6). Maximal CAT gene expression, however, is only achieved when both interleukin-1 beta (IL-1 beta) and IL-6 are present. The response to the two cytokines is cooperative. Cooperativity is maintained when the CRP promoter is linked to a different coding region, that of the bacterial neomycin phosphotransferase II gene. With a series of 5' and 3' deletions we show the existence of two distinct and independent regions responsive to IL-6 and located upstream to the TATA box. The IL-1 effect is exerted at the level of downstream sequences that are probably important for optimal mRNA translatability or nuclear-cytoplasmic transport. Inducibility is not influenced by the activation of protein kinases C or A and does not require new protein synthesis.

References

    1. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7251-5
    1. EMBO J. 1987 Jul;6(7):1905-12
    1. J Immunol. 1987 Dec 15;139(12):4122-8
    1. Methods Enzymol. 1987;155:111-9
    1. Mol Biol Med. 1987 Dec;4(6):323-38
    1. EMBO J. 1987 Dec 20;6(13):4017-22
    1. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2171-5
    1. Nucleic Acids Res. 1988 Apr 25;16(8):3195-207
    1. FEBS Lett. 1988 May 23;232(2):347-50
    1. Annu Rev Immunol. 1988;6:485-512
    1. Science. 1988 Jul 29;241(4865):585-9
    1. Science. 1988 Aug 12;241(4867):825-8
    1. J Biol Chem. 1988 Sep 5;263(25):12554-8
    1. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6802-5
    1. Biochem Biophys Res Commun. 1988 Nov 30;157(1):271-7
    1. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9503-7
    1. Mol Cell Biol. 1988 Aug;8(8):3546-9
    1. J Biol Chem. 1989 May 5;264(13):7669-74
    1. EMBO J. 1989 Apr;8(4):1145-51
    1. Virology. 1973 Apr;52(2):456-67
    1. Methods Enzymol. 1975;43:611-28
    1. Science. 1980 Jul 25;209(4455):497-9
    1. Ann N Y Acad Sci. 1982;389:39-48
    1. Methods Enzymol. 1983;101:20-78
    1. Adv Immunol. 1983;34:141-212
    1. Annu Rev Biochem. 1984;53:75-117
    1. J Exp Med. 1985 Sep 1;162(3):930-42
    1. Cell. 1986 Apr 25;45(2):201-7
    1. Science. 1986 May 16;232(4752):850-2
    1. J Biol Chem. 1986 Jun 25;261(18):8077-80
    1. J Biol Chem. 1986 Jun 25;261(18):8453-61
    1. Cell. 1986 Aug 29;46(5):705-16
    1. J Cell Biol. 1986 Sep;103(3):787-93
    1. J Clin Invest. 1986 Nov;78(5):1349-54
    1. Science. 1987 Feb 13;235(4790):731-2
    1. Nucleic Acids Res. 1987 Apr 10;15(7):3085-96
    1. Biochemistry. 1987 Mar 24;26(6):1563-8
    1. Nature. 1987 Jun 25-Jul 1;327(6124):727-30
    1. J Biol Chem. 1987 Aug 5;262(22):10850-4
    1. Eur J Immunol. 1987 Aug;17(8):1193-7
    1. EMBO J. 1987 Sep;6(9):2759-66

Source: PubMed

3
Abonnieren